BEVERLEY CARR

Chief Business Officer, Achilles

Beverley was previously Vice President, Business Development, for the Immunoinflammation Therapy Area at GSK, where she led over twenty business development transactions within R&D. Her experience includes discovery collaborations, M&A, equity transactions, company creation, late-stage product partnering deals, and GSK’s major strategic transaction with Novartis. Beverley was a member of GSK’s Immunoinflammation Leadership Team, the Worldwide Business Development Leadership Team, the Portfolio Progression Team and the Technology Investment Board.

Prior to joining GSK, Beverley led business development transactions at Cambridge Antibody Technology and Arakis and was a management consultant within the PA Consulting Life Science Strategy Practice.

She is a scientist by training with an MA and DPhil in chemistry from Oxford University and has an MBA from Cambridge University.